Journal
LEUKEMIA & LYMPHOMA
Volume 57, Issue 10, Pages 2259-2267Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2016.1195501
Keywords
Intermediate-1 risk; International Prognostic Scoring System; myelofibrosis; ruxolitinib; splenomegaly
Categories
Funding
- Incyte Corporation
- Medical Research Council [MR/L006340/1] Funding Source: researchfish
- MRC [MR/L006340/1] Funding Source: UKRI
Ask authors/readers for more resources
Ruxolitinib is the only therapy with an approved indication for myelofibrosis (MF), a myeloproliferative neoplasm associated with progressive bone marrow fibrosis and extramedullary hematopoiesis. Although the pivotal phase 3 COMFORT studies included only patients with intermediate-2 or high-risk MF, the US indication includes all patients with intermediate- or high-risk disease. Data from recent nonrandomized studies confirm that the benefits of ruxolitinib established in the COMFORT studies in terms of spleen size reduction and symptom improvement also extend to patients with intermediate-1 risk MF, who tend to have less advanced disease than patients with higher-risk MF. Given the disease-modifying potential of ruxolitinib therapy, timely initiation of ruxolitinib therapy may not only improve patients' current clinical status but also lead to better long-term outcomes. The decision of whether or when to initiate ruxolitinib treatment should be based on the expected benefit-risk ratio for each patient, specifically considering potential adverse effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available